Delivery Order SPE2DB20D3303-SPE2DB25FA2KX
- Not listed
- The Defense Logistics Agency awarded a $18,415.47 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and represents a direct delivery of pharmaceutical products to support federal healthcare operations. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a $43,038.15 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 mL pens with an ultimate completion date of August 11, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award for pharmaceutical supply to support federal medical procurement needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $8,322.75. This firm fixed price delivery order, which is set to be completed by August 28, 2025, will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a non-set-aside, competitively awarded contract issued under AmerisourceBergen's existing pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $110,776.11 for Dupixent 300 mg/2 mL pens on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded procurement supporting federal pharmaceutical supply needs. The contract will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $12,806.82 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 26, 2025. This firm fixed price, non-competitive delivery order will be fulfilled from the vendor's place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 27, 2025. The award represents a single transaction under AmerisourceBergen's broader federal pharmaceutical supply portfolio serving...
- The Defense Logistics Agency awarded a delivery order valued at $35,006.30 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 18, 2025, with an ultimate completion date of August 19, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The pharmaceutical product will be delivered to the company's place of performance in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $7,945.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 11, 2025, with a completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply framework. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,128.38 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on September 5, 2025, with an ultimate completion date of September 8, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award under the company's existing DLA contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the performing...
- On August 5, 2025, the Defense Logistics Agency awarded a delivery order valued at $48,364.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections. This firm fixed-price delivery order, which is not set-aside designated, represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The products will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $27,179.45 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens with a completion date of September 3, 2025. This non-set-aside contract represents a single delivery order fulfillment under the company's broader pharmaceutical supply agreement with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor providing critical medical commodities to federal...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2KXDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,416.48 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed price delivery order, which carries no set-aside designation, represents a competitive award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The product will be delivered to the same location, supporting the Defense Logistics Agency's Medical Supply Chain operations. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The IDC demonstrates AmerisourceBergen's established capability to fulfill federal medical procurement requirements and represents the company's significant role as a critical vendor for military and veteran healthcare systems. The award reflects the ongoing pharmaceutical support needs of the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.4k | 8/12/25 |